{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:51:18Z","timestamp":1777269078388,"version":"3.51.4"},"reference-count":106,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>For patients with myelodysplastic neoplasm\/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment clinical trials have indicated that in eligible patients, allo-HCT is associated with superior clinical outcomes compared with nontransplant therapy. However, this therapeutic option is only available to a subset of patients, and the outcome is influenced by multiple factors inherent to the patient, the MDS subtype, and the allo-HCT procedure itself. In 2017, the European Society for Blood and Marrow Transplantation (EBMT) published recommendations for allo-HCT in MDS to guide practical decision making. In the contemporary era, genomic profiling has become routine clinical practice in many centers, and the most recent classification systems include MDS entities that are defined by genetic abnormalities. In particular, the molecular International Prognostic Scoring System offers more precise prognostication across all clinical end points and currently represents the standard tool for estimating patient survival in the absence of disease-modifying treatment. Evidence from multiple sources increasingly indicates that allo-HCT should be considered at the time of diagnosis in all eligible patients with MDS. Therefore, genomic profiling for somatic mutations and testing for germ line predisposition variants are integral to determining a patient\u2019s eligibility for transplantation. Although all patients with higher-risk MDS are potential candidates for immediate transplantation, a subset of those with lower-risk MDS may also derive benefit from this procedure at an earlier disease stage. Comprehensive recommendations on behalf of an expert international panel for clinical practice and future clinical studies of relevance are presented.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025131","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:58:03Z","timestamp":1739995083000},"page":"1987-2001","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"first","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"},{"name":"2Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[{"name":"3Department of Hematology, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[{"name":"3Department of Hematology, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"4Cancer Center for Excellence, King Faisal Cancer Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-0928","authenticated-orcid":false,"given":"Antonio","family":"Almeida","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital da Luz Lisboa, Lisbon, Portugal, and Faculdade de Medicina, Universidade Cat\u00f3lica Portuguesa, Rio de Mouro, Portugal"}]},{"given":"Fernando Barroso","family":"Duarte","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hospital Universitario Walter Cant\u00eddio, Universidade Federal do Ceara, Fortaleza, Brazil"}]},{"given":"Elsa","family":"Bernard","sequence":"additional","affiliation":[{"name":"7Department of Computational Oncology, UMR 981, Gustave Roussy, Villejuif, France"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[{"name":"8Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-5970","authenticated-orcid":false,"given":"Matteo Giovanni","family":"Della Porta","sequence":"additional","affiliation":[{"name":"9Comprehensive Cancer Center, IRCCS Humanitas Clinical and Research Center and Department of Biomedical Sciences, Humanitas University, Milan, Italy"}]},{"given":"Theo","family":"De Witte","sequence":"additional","affiliation":[{"name":"10Department of Tumor Immunology, Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands"}]},{"given":"Amy","family":"DeZern","sequence":"additional","affiliation":[{"name":"11Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Sokolowska","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}]},{"given":"Eric","family":"Duncavage","sequence":"additional","affiliation":[{"name":"13Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"3Department of Hematology, H\u00f4pital Saint Louis, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[{"name":"14Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"15Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"16Munich Leukemia Laboratory, Munich, Germany"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"16Munich Leukemia Laboratory, Munich, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-0697","authenticated-orcid":false,"given":"Robert","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"17Department of Pathology, Massachusetts General Hospital, Boston, MA"}]},{"given":"Eva","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Karolinska University Hospital, and Centre of Hematology and Regenerative Medicine, Institution of Medicine, Karolinska Institute, Huddinge, Sweden"}]},{"given":"Meagan","family":"Jacoby","sequence":"additional","affiliation":[{"name":"19Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"20Department of Haematology, King\u2019s College Hospital, London, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[{"name":"8Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"2Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-8578","authenticated-orcid":false,"given":"Hideki","family":"Makishima","sequence":"additional","affiliation":[{"name":"21Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-1611","authenticated-orcid":false,"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"22Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-9119","authenticated-orcid":false,"given":"Moshe","family":"Mittelman","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel"}]},{"given":"Anders E.","family":"Myhre","sequence":"additional","affiliation":[{"name":"24Department of Haematology, Oslo University Hospital, Oslo, Norway"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"25Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"26Department of Hematology-Bone Marrow Transplant, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy"}]},{"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[{"name":"27Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"28Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"29Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany"},{"name":"30University Hospital Dresden, Dresden, Germany"}]},{"given":"Lisa","family":"Pleyer","sequence":"additional","affiliation":[{"name":"31Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-354X","authenticated-orcid":false,"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[{"name":"32Department of Haematology and Stem Cell Transplantation, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-2172","authenticated-orcid":false,"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[{"name":"33MDS Unit, Hematology, Department of Experimental and Clinical Medicine, Azienda Ospedaliero Universitaria Careggi Medical School, University of Florence, Florence, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"34Institut Catal\u00e0 d'Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-5852","authenticated-orcid":false,"given":"Magnus","family":"Tobiasson","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Karolinska University Hospital, and Centre of Hematology and Regenerative Medicine, Institution of Medicine, Karolinska Institute, Huddinge, Sweden"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[{"name":"1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[{"name":"35Centre Hospitalier Universitaire de Lille, University of Lille, INSERM U1286, INFINITE 59000, Lille, France"}]},{"given":"Amer","family":"Zeidan","sequence":"additional","affiliation":[{"name":"36Department of Hematology and Oncology, Yale University, New Haven, CT"}]},{"given":"Matthew","family":"Walter","sequence":"additional","affiliation":[{"name":"19Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"14Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[{"name":"32Department of Haematology and Stem Cell Transplantation, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-8817","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"22Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy"}]}],"member":"234","reference":[{"issue":"14","key":"2025050111220256400_bib1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025050111220256400_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025050111220256400_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"2025050111220256400_bib4","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1182\/blood.2023020079","article-title":"Clinical decision-making and treatment of myelodysplastic syndromes","volume":"142","author":"Hellstrom-Lindberg","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025050111220256400_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on practice guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"2025050111220256400_bib6","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"30","key":"2025050111220256400_bib7","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025050111220256400_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2025050111220256400_bib9","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"33","key":"2025050111220256400_bib10","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025050111220256400_bib11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025050111220256400_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2025050111220256400_bib13","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025050111220256400_bib14","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"2025050111220256400_bib15","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"2025050111220256400_bib16","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"15","key":"2025050111220256400_bib17","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"2025050111220256400_bib18","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 study","volume":"41","author":"Versluis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2025050111220256400_bib19","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2025050111220256400_bib20","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.24.00649","article-title":"Revisiting timing and decision modeling for allogeneic hematopoietic stem-cell transplantation in myelodysplastic syndromes","volume":"42","author":"Cutler","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2025050111220256400_bib21","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025050111220256400_bib22","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025050111220256400_bib23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.2023023723","article-title":"Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes","volume":"144","author":"Sirenko","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2025050111220256400_bib24","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025050111220256400_bib25","first-page":"312","article-title":"Genome sequencing in the management of myelodysplastic syndromes and related disorders","volume":"110","author":"Cazzola","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"2025050111220256400_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"issue":"7","key":"2025050111220256400_bib27","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/leu.2015.37","article-title":"HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM","volume":"29","author":"Robin","year":"2015","journal-title":"Leukemia"},{"issue":"30","key":"2025050111220256400_bib28","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kroger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2025050111220256400_bib29","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2025050111220256400_bib30","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.21.01594","article-title":"Two biologic-assignment studies evaluating the efficacy of hematopoietic cell transplant among older patients with high-risk myelodysplastic syndrome","volume":"39","author":"Gooley","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025050111220256400_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ajh.26768","article-title":"Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102","volume":"98","author":"Cusatis","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2025050111220256400_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/OP.23.00413","article-title":"Cost-effectiveness of reduced-intensity allogeneic hematopoietic cell transplantation for older patients with high-risk myelodysplastic syndrome: analysis of BMT CTN 1102","volume":"20","author":"Saber","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"2025050111220256400_bib33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2025050111220256400_bib34","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kroger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025050111220256400_bib35","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bmt.2017.19","article-title":"Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes","volume":"52","author":"Martino","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025050111220256400_bib36","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase\u00a03\u00a0trial","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025050111220256400_bib37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2025050111220256400_bib38","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1182\/bloodadvances.2023010850","article-title":"Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities","volume":"7","author":"Popat","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025050111220256400_bib39","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41409-024-02282-7","article-title":"Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)","volume":"59","author":"Niederwieser","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2025050111220256400_bib40","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \"when and for whom\" in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"2025050111220256400_bib41","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"issue":"18","key":"2025050111220256400_bib42","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv"},{"issue":"26","key":"2025050111220256400_bib43","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"2025050111220256400_bib44","doi-asserted-by":"crossref","first-page":"101128","DOI":"10.1016\/j.blre.2023.101128","article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","volume":"62","author":"Stahl","year":"2023","journal-title":"Blood Rev"},{"issue":"11","key":"2025050111220256400_bib45","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2025050111220256400_bib46","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/bloodadvances.2020002306","article-title":"Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing","volume":"4","author":"Lucas","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2025050111220256400_bib47","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3390\/cancers15082305","article-title":"Myeloid NGS analyses of paired samples from bone marrow and peripheral blood yield concordant results: a prospective cohort analysis of the AGMT Study Group","volume":"15","author":"Jansko-Gadermeir","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2025050111220256400_bib48","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2025050111220256400_bib49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41375-023-01820-4","article-title":"Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M","volume":"37","author":"Gurnari","year":"2023","journal-title":"Leukemia"},{"issue":"16","key":"2025050111220256400_bib50","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2015.65.0515","article-title":"Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome","volume":"34","author":"Shaffer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025050111220256400_bib51","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3324\/haematol.2018.200808","article-title":"Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation","volume":"104","author":"Gagelmann","year":"2019","journal-title":"Haematologica"},{"issue":"13","key":"2025050111220256400_bib52","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood.2022017715","article-title":"DDX41-associated susceptibility to myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"24","key":"2025050111220256400_bib53","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025050111220256400_bib54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","article-title":"Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies","volume":"7","author":"Saygin","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2025050111220256400_bib55","doi-asserted-by":"crossref","first-page":"e994","DOI":"10.1016\/S2352-3026(23)00265-X","article-title":"Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Gurnari","year":"2023","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025050111220256400_bib56","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation","volume":"42","author":"Tobiasson","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025050111220256400_bib57","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.leu.2405076","article-title":"Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-\/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies","volume":"22","author":"Huang","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2025050111220256400_bib58","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT","volume":"8","author":"Gurnari","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025050111220256400_bib59","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","article-title":"Allogenic haematopoietic stem cell transplantation in VEXAS: a review of 33 patients","volume":"43","author":"Ali","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2025050111220256400_bib60","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025050111220256400_bib61","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ajh.27228","article-title":"Age barriers in allogeneic hematopoietic cell transplantation: raising the silver curtain","volume":"99","author":"Munshi","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"2025050111220256400_bib62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","article-title":"Comparison of patient age groups in transplantation for myelodysplastic syndrome: the Medicare coverage with evidence development study","volume":"6","author":"Atallah","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"2025050111220256400_bib63","doi-asserted-by":"crossref","first-page":"635","DOI":"10.6004\/jnccn.2020.7559","article-title":"Eligibility criteria for patients undergoing allogeneic hematopoietic cell transplantation","volume":"18","author":"Kanate","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"8","key":"2025050111220256400_bib64","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"27","key":"2025050111220256400_bib65","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025050111220256400_bib66","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41375-019-0666-7","article-title":"An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic\u00a0scoring","volume":"34","author":"Starkman","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2025050111220256400_bib67","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2025050111220256400_bib68","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/hematology.2019000041","article-title":"Integrating patient-centered factors in the risk assessment of MDS","volume":"2019","author":"Buckstein","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2025050111220256400_bib69","doi-asserted-by":"crossref","first-page":"afad058","DOI":"10.1093\/ageing\/afad058","article-title":"Frailty transitions and prevalence in an ageing population: longitudinal analysis of primary care data from an open cohort of adults aged 50 and over in England, 2006-2017","volume":"52","author":"Walsh","year":"2023","journal-title":"Age Ageing"},{"issue":"4","key":"2025050111220256400_bib70","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.2023022500","article-title":"How I manage iron overload in the hemopoietic cell transplantation setting","volume":"145","author":"Angelucci","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2025050111220256400_bib71","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/bmt.2016.40","article-title":"Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?","volume":"51","author":"El-Jawahri","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2025050111220256400_bib72","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A\u00a0decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2025050111220256400_bib73","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23458","article-title":"Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome","volume":"88","author":"Alessandrino","year":"2013","journal-title":"Am J Hematol"},{"issue":"21","key":"2025050111220256400_bib74","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025050111220256400_bib75","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/leu.2017.88","article-title":"Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System","volume":"31","author":"Della Porta","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2025050111220256400_bib76","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/leu.2012.210","article-title":"Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings","volume":"27","author":"Kroger","year":"2013","journal-title":"Leukemia"},{"issue":"24","key":"2025050111220256400_bib77","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood.2023023697","article-title":"Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT","volume":"143","author":"Sanz","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025050111220256400_bib78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2025050111220256400_bib79","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41409-023-01931-7","article-title":"Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS","volume":"58","author":"Michel","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2025050111220256400_bib80","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2025050111220256400_bib81","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","article-title":"Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia","volume":"25","author":"Schroeder","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2025050111220256400_bib82","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1080\/10428194.2019.1605070","article-title":"Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome","volume":"60","author":"Modi","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025050111220256400_bib83","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2020.01.030","article-title":"Impact of treatment prior to allogeneic transplantation of hematopoietic stem cells in patients with myelodysplastic syndrome: results of the Latin American Bone Marrow Transplant registry","volume":"26","author":"Duarte","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2025050111220256400_bib84","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdx154","article-title":"Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study","volume":"28","author":"Voso","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"2025050111220256400_bib85","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2023022273","article-title":"Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?","volume":"144","author":"Scheid","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025050111220256400_bib86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.17817","article-title":"Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT","volume":"195","author":"Shimoni","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2025050111220256400_bib87","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2025050111220256400_bib88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2025050111220256400_bib89","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2025050111220256400_bib90","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbmt.2017.12.776","article-title":"Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation","volume":"24","author":"Shimoni","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2025050111220256400_bib91","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41409-023-02111-3","article-title":"Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT","volume":"59","author":"Potter","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025050111220256400_bib92","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.2830270108","article-title":"Genotypic analysis using a Y-chromosome-specific probe following bone marrow transplantation","volume":"27","author":"Morisaki","year":"1988","journal-title":"Am J Hematol"},{"issue":"6","key":"2025050111220256400_bib93","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood.V74.6.2220.2220","article-title":"Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay","volume":"74","author":"Durnam","year":"1989","journal-title":"Blood"},{"issue":"2","key":"2025050111220256400_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.1989.tb00253.x","article-title":"Chimaerism following allogeneic bone marrow transplantation: detection of residual host cells using the polymerase chain reaction","volume":"73","author":"Lawler","year":"1989","journal-title":"Br J Haematol"},{"issue":"11","key":"2025050111220256400_bib95","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood.V77.11.2504.2504","article-title":"Evaluation of mixed chimerism by in\u00a0vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction","volume":"77","author":"Lawler","year":"1991","journal-title":"Blood"},{"issue":"7","key":"2025050111220256400_bib96","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.V87.7.3027.bloodjournal8773027","article-title":"Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors","volume":"87","author":"Molloy","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2025050111220256400_bib97","first-page":"415","article-title":"High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells","volume":"26","author":"Briones","year":"1998","journal-title":"Exp Hematol"},{"key":"2025050111220256400_bib98","author":"Thomas","year":"2004","edition":"3rd ed"},{"issue":"3","key":"2025050111220256400_bib99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jmoldx.2017.01.005","article-title":"Haplotype counting for sensitive chimerism testing: Potential for early leukemia relapse\u00a0detection","volume":"19","author":"Debeljak","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"issue":"4","key":"2025050111220256400_bib100","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3892\/mmr.2016.5593","article-title":"A\u00a0technical application of quantitative next generation sequencing for chimerism evaluation","volume":"14","author":"Aloisio","year":"2016","journal-title":"Mol Med Rep"},{"issue":"12","key":"2025050111220256400_bib101","first-page":"2077","article-title":"Simultaneous monitoring of mutation and chimerism using next-generation sequencing in myelodysplastic syndrome","volume":"8","author":"Lee","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"14","key":"2025050111220256400_bib102","doi-asserted-by":"crossref","first-page":"11814","DOI":"10.3390\/ijms241411814","article-title":"Chimerism testing by next generation sequencing for detection of engraftment and early disease relapse in allogeneic hematopoietic cell transplantation and an overview of NGS chimerism studies","volume":"24","author":"Liacini","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2025050111220256400_bib103","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.bbmt.2019.06.007","article-title":"A\u00a0phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (Alliance)","volume":"25","author":"Vij","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2025050111220256400_bib104","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A\u00a0phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025050111220256400_bib105","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/cas.15048","article-title":"Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"112","author":"Wei","year":"2021","journal-title":"Cancer Sci"},{"issue":"12","key":"2025050111220256400_bib106","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/18\/1987\/2372248\/blood_bld-2024-025131-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/18\/1987\/2372248\/blood_bld-2024-025131-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T15:22:37Z","timestamp":1746112957000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/18\/1987\/535649\/Clinical-genomic-profiling-of-MDS-to-inform-allo"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":106,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025131","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}